According to Zhito Finance APP, JiAYin International has maintained a target price of HKD 183 for Akeso (09926) and continues to strongly endorse a 「Buy」 rating. The firm noted that the company's overseas development is progressing well, with a series of catalysts expected in the next 1-2 years. Additionally, Summit Therapeutics recently announced an expansion of its overseas research scale for Ivosidenib. The report highlighted that the second head-to-head Phase III study of Ivosidenib has returned strong positive data, indicating that the median progression-free survival (PFS) for Ivosidenib significantly outperforms other single-target PD-1 therapies. Furthermore, the absolute improvement in PFS compared to PD-1 has exceeded the enhancement observed with traditional chemotherapy. The firm maintains its expectation for peak sales in mainland China to reach RMB 7.1 billion.